Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;25(4):409-423.
doi: 10.1111/hiv.13595. Epub 2023 Dec 18.

HIV and type 2 diabetes: An evolving story

Harriet Daultrey  1 , Tom Levett  1 , Nick Oliver  2 , Jaime Vera  1 , Ali J Chakera  1
Affiliations
Review

HIV and type 2 diabetes: An evolving story

Harriet Daultrey et al. HIV Med. 2024 Apr.

Abstract

Introduction: Diabetes is widely reported to be more common in people living with HIV (PLWH). Much of the data supporting this originated during the earlier HIV era. The perceived increased risk of type 2 diabetes is reflected in HIV clinical guidelines that recommend screening for diabetes in PLWH on anti-retroviral therapy (ART). However, international HIV clinical guidelines do not agree on the best marker of glycaemia to screen for diabetes. This stems from studies that suggest HbA1c underestimates glycaemia in PLWH.

Methods: Within this review we summarise the literature surrounding the association of HIV and type 2 diabetes and how this has changed over time. We also present the evidence on HbA1c discrepancy in PLWH.

Conclusion: We suggest there is no basis to any international guidelines to restrict HbA1c based on HIV serostatus. We recommend, using the current evidence, that PLWH should be screened annually for diabetes in keeping with country specific guidance. Finally, we suggest future work to elucidate phenotype and natural history of type 2 diabetes in PLWH across all populations.

Keywords: HIV; HbA1c; diagnosis; type 2 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. IDF. International Diabetes Federation Diabetes Atlas. 10th ed.; 2021.
    1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of type 2 diabetes‐global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107‐111.
    1. Group TAC. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560‐2572.
    1. Lachin JM, Nathan DM. Understanding metabolic memory: the prolonged influence of glycemia during the diabetes control and complications trial (dcct) on future risks of complications during the study of the epidemiology of diabetes interventions and complications (edic). Diabetes Care. 2021;44(10):2216‐2224. Available from: https://care.diabetesjournals.org/content/early/2021/09/22/dc20‐3097
    1. Nathan DM. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (EDIC) study. J Am Med Assoc. 2003;290(16):2159‐2167. Available from: https://pubmed.ncbi.nlm.nih.gov/14570951/

MeSH terms

LinkOut - more resources